Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399025 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US8877245 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US9375410 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US7790199 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US7820203 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US7829121 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US7544372 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
US7387793 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Feb, 2025
(10 months from now) |
Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 February, 2007
Treatment: Relief of muscle spasm
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7842687 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
USRE45128 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml); Treatment of patients with leukemia including chronic myeloid/myelogenous...
Dosage: POWDER;SUBCUTANEOUS